Jason E. Baranski
Director/Board Member bei DYAX CORP.
Profil
Jason E.
Baranski is currently serving as Secretary & Director at Dyax Corp., Shire US, Inc., Shire Human Genetic Therapies, Inc., Lotus Tissue Repair, Inc., and as Secretary at ARIAD Pharmaceuticals, Inc. He previously served as Secretary & Director at BIKAM Pharmaceuticals, Inc.
Aktive Positionen von Jason E. Baranski
| Unternehmen | Position | Beginn |
|---|---|---|
| DYAX CORP. | Director/Board Member | - |
| ARIAD PHARMACEUTICALS, INC. | Corporate Secretary | - |
Shire US, Inc.
 Shire US, Inc. Medical DistributorsDistribution Services Shire US, Inc. sells and markets prescription medicines. The company was founded on September 28, 1983 and is headquartered in Lexington, MA. | Director/Board Member | - |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Director/Board Member | - |
Lotus Tissue Repair, Inc.
 Lotus Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA. | Director/Board Member | - |
Ehemalige bekannte Positionen von Jason E. Baranski
| Unternehmen | Position | Ende |
|---|---|---|
BIKAM Pharmaceuticals, Inc.
 BIKAM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BIKAM Pharmaceuticals, Inc. develops ophthalmic pharmaceuticals products. It focuses on the discovery and development of novel drugs for degenerative diseases of the eye. The company was founded on June 12, 2007 by Shalesh Kaushal and is headquartered in Lexington, MA. | Director/Board Member | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
BIKAM Pharmaceuticals, Inc.
BIKAM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BIKAM Pharmaceuticals, Inc. develops ophthalmic pharmaceuticals products. It focuses on the discovery and development of novel drugs for degenerative diseases of the eye. The company was founded on June 12, 2007 by Shalesh Kaushal and is headquartered in Lexington, MA. | Health Technology |
Shire US, Inc.
Shire US, Inc. Medical DistributorsDistribution Services Shire US, Inc. sells and markets prescription medicines. The company was founded on September 28, 1983 and is headquartered in Lexington, MA. | Distribution Services |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
Lotus Tissue Repair, Inc.
Lotus Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA. | Health Technology |
